Abstract 1914P
Background
VEGF and FGFR play major roles in MPM tumorigenesis. Bevacizumab(bev)-platinum-pemetrexed (PP) with bev maintenance improved progression-free (PFS) and overall survival (OS) in the MAPS trial. N is an angiokinase inhibitor with antifibrotic properties targeting VEGF1-3, PDGFRA/B, FGFR1-3, SRC, ABL. VEGF inhibitors previously showed encouraging activity and N’s role as switch maintenance remained unknown. During enrolment, the LUME-Meso phase III trial reported no OS improvement for N-PP and N maintenance in epithelioid MPM and cediranib-PP demonstrated no significant PFS benefit (SWOG S0905).
Methods
We enrolled treatment naïve unresectable MPM (all histology), adequate organ function, no unstable co-morbidities, no N contraindication, performance status 0-2 and no progression after 4-6 cycles PP. Patients(pts) were randomized to N 200mg BID or placebo, continued until loss of clinical benefit, toxicity, or death. Primary endpoint was PFS, secondary endpoints were OS, time to treatment failure (TTF), overall response rate (ORR) and safety. 114 pts were planned for recruitment to target PFS HR=0.62.
Results
The study closed due to poor accrual with 37 pts randomized. We present final analyses. Demographics/efficacy shown (Table). Grade≥3 adverse events (AEs) were observed in 27.8%(N) vs 10.5%(placebo), no deaths from toxicity. Commonest AEs were typical for N. Table: 1914P
N, n=18 | Placebo, n=19 | HR (95% CI) | |
Median follow up (mo) | 48.7 | 42.4 | |
M:F (n) | 12:6 | 15:4 | |
Epithelioid (%) | 78 | 79 | |
Median treatment duration (weeks) | 11.8 | 24.3 | |
PFS (mo) | 3.4 | 4.6 | 2.25 (1.07-4.73) |
OS (mo) | 13.1 | 38.9 | 2.38 (1.05-5.43) |
TTF (mo) | 2.0 | 4.6 | 2.55 (1.22-5.32) |
Further anticancer treatment (%) | 72 | 79 | |
Further immunotherapy (%) | 46 | 87 |
Conclusions
Despite closing early, whilst imbalanced by subsequent immunotherapy use, NEMO suggests a detrimental effect of maintenance N compared with placebo (Sponsor, EORTC; Funding, Boehringer Ingelheim/EORTC; NCT02863055).
Clinical trial identification
EORTC-08112-LCG; NCT02863055.
Editorial acknowledgement
Legal entity responsible for the study
EORTC.
Funding
Boehringer Ingelheim.
Disclosure
S. Popat: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Novartis, Amgen, Janssen, Daiichi Sankyo, AstraZeneca, Bayer, BMS, Blueprint, Merck Serono, Guardant Health, Takeda, Lilly, Roche, Turning Point Therapeutics, GSK, MSD, Pfizer, Sanofi, EQRx, AnHeart, Arcus Biosciences, Ellipses, Gilead, IO Biotech, Mirati; Financial Interests, Personal, Invited Speaker: Medscape, VJ Oncology, Novocure, PharmaMar; Financial Interests, Institutional, Other, Sub-investigator: Amgen; Financial Interests, Institutional, Coordinating PI: Ariad, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Takeda, Turning Point Therapeutics, Roche, Janssen, BMS, Lilly; Financial Interests, Institutional, Local PI: AstraZeneca, Roche, GSK, Trizel; Financial Interests, Institutional, Other, Sub-Investigator: MSD, Blueprint; Financial Interests, Institutional, Research Grant: Guardant Health; Non-Financial Interests, Leadership Role, Chair of Steering Committee, Unpaid: British Thoracic Oncology Group; Non-Financial Interests, Officer, Thoracic Faculty, Unpaid: European Society of Medical Oncology; Non-Financial Interests, Leadership Role, Foundation Council Member, Unpaid: European Thoracic Oncology Platform; Non-Financial Interests, Advisory Role, Mesothelioma Committee, Unpaid: International Association for the Study of Lung Cancer; Non-Financial Interests, Member of Board of Directors, Unpaid: Mesothelioma Applied Research Foundation; Non-Financial Interests, Advisory Role, Honorary Clinical Advisor, Unpaid: ALK Positive UK; Non-Financial Interests, Advisory Role, Research Advisory Group Member, Unpaid: Ruth Strauss Foundation; Non-Financial Interests, Advisory Role, Scientific Advisory Board Member, Unpaid: Lung Cancer Europe. All other authors have declared no conflicts of interest.
Resources from the same session
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18
Resources:
Abstract
1927P - AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study
Presenter: Feng Shi
Session: Poster session 18
Resources:
Abstract
1928P - Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): A prospective, open-label, phase II study
Presenter: Jun Cao
Session: Poster session 18
Resources:
Abstract
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
Resources:
Abstract
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
Resources:
Abstract
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
Resources:
Abstract
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
Resources:
Abstract
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
Resources:
Abstract
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
Resources:
Abstract
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18
Resources:
Abstract